PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)

The studies showed that the isolated compounds could be used for the development of anticancer therapies.

Given the rarity of the tumor, it is crucial to distinguish it from morphological mimics to inform appropriate patient management. Treatment approaches are typically based on protocols for primary breast cancer, given the histological and biological similarities between these tumors and breast tissue.

Commonly altered genes included PIK3CA (57%), CDH1 (57%), and TP53 (57%). These validated ILC PDX models provide valuable tools to advance understanding of ILC biology and support development of targeted therapies.

P2, N=80, Recruiting, Hoffmann-La Roche | N=44 --> 80 | Trial completion date: Dec 2030 --> Feb 2030

Although less potent than the nanomolar-range reference drug Epothilone B (IC50 < 0.1 μM), rugulosin A showed submicromolar-to-low micromolar efficacy with notable selectivity toward cancer cells, which is considered significant for an unoptimized natural product scaffold. Its antiproliferative activity against K562 cells (GI50 = 3.69 μM), benchmarked against Imatinib (GI50 = 0.373 μM), also falls within the active range of natural product leads...Molecular docking revealed strong binding energies (-10.1, -9.8, and -11.0 kcal/mol), along with a stable molecular dynamics simulations data. These findings highlight rugulosin A (3) as a promising anticancer lead that modulates major apoptosis signaling pathways.

For condylomas with concurrent HSIL, 43% recurred and 9% progressed to SCC. Condylomas with concurrent SCC were associated with mutations in ASXL1, TERT and CDKN2A/CDKN2B while warty SCC was associated with mutations in PIK3CA, KMT2C and FAT1.

The mutational patterns affecting homologous recombination repair differ across gynecologic and breast cancers. Further research into cancer-specific HRD mechanisms is warranted.

Concurrent targeting of PI3K and IR/IGF-1R signaling effectively overcomes adaptive resistance in PIK3CA-mutant NSCLC, supporting the rationale for further clinical evaluation of this combined therapeutic strategy.

Fusion transcript analysis identified 91 recurrent fusions, including novel partners with ERBB2, MED1, and CDK12, suggesting the possibility of unique molecular events. Interpretation and conclusions This study demonstrates that Indian breast cancer patients exhibit molecular subtypes and actionable mutations comparable to Caucasian cohorts.

NSCLCs harboring ECD-ERBB2 mutations are associated with a unique clinico-genomic phenotype and improved outcomes with first-line chemoimmunotherapy. These findings have implications for optimizing treatment strategies in this disease.

This study systematically elucidates the multi-component, multi-target, and multi-pathway mechanisms underlying Epimedium's anti-ovarian cancer effects, thereby providing a theoretical foundation for its potential clinical application. It should be noted, however, that these findings are computational predictions and thus require experimental validation.